All In MedTech

Device Trial Radar · NCT06264427

Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jul 15, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Steno Diabetes Center GreenlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zealand University Hospital; University of Copenhagen
First posted
Feb 20, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: * Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: * Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing

Conditions

  • Diabetes Mellitus, Type 2
  • Obesity, Morbid
  • Obstructive Sleep Apnea
  • MODY
  • Diabetic Retinopathy
  • Diabetic Neuropathies

Interventions

  • Whole genome sequencingGenetic

    Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.

  • VAGUSDiagnostic test

    To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN

  • NightOwlDiagnostic test

    Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.

  • CPAPDevice

    Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with MODY diabetes and their complication statusTime frame: Blood drawn at inclusion. Results for participants ready after approximately 6 months.
  2. Number of participants with diabetic complicationTime frame: Types and number of complications are available at inclusion. No follow-up screenings for complications are performed.
  3. Number of participants with obstructive sleep apneaTime frame: Home sleep testing is performed for 3 nights after inclusion. Confirmatory home sleep examinations performed one day after the initial sleep examination. In total, four days examinations time.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Steno Diabetes Center Greenland, Queen Ingrids Hospital

    Nuuk, Sermersooq, Greenland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.